Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy while Personalis completes its clinical validation in more indications.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy
Premium
Investigators showed that patients who are positive for ctDNA at the time of their fourth induction treatment have poorer outcomes and could benefit from new strategies.
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
Natera Sues NeoGenomics for Patent Infringement
Natera alleges that NeoGenomics is infringing on two patents related to the Signatera minimal residual disease testing platform.